Payment overview · 2025
General Payments
$1,647.71
81 reported records · 20 companies
Healthcare provider profile · identity verified
Nathan J. Hall, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1679515431
Verified facts
What the public records show
CMS Open Payments records show Nathan J. Hall, M.D. received $1,647.71 in general payments during 2025 across 81 reported records.
Lilly USA, LLC accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $241.03 | 14.6% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $225.94 | 13.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $216.01 | 13.1% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $144.71 | 8.8% | 8 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.24 | 8.4% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $137.35 | 8.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.21 | 5.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.62 | 5.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.88 | 4.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.13 | 3.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.12 | 2.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.23 | 2.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.54 | 1.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.42 | 1.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.60 | 1.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.90 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.21 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.46 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.56 | 0.9% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.55 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,647.71 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $195.60 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $183.13 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.08 | 7 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $138.24 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $137.35 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $110.59 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $101.81 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $101.81 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $101.80 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $98.65 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $93.21 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $86.20 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.62 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.23 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.67 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $58.33 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.12 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 187 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 76 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
187 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1009 | 283 |
| Amlodipine Besylate | Amlodipine Besylate | 805 | 226 |
| Losartan Potassium | Losartan Potassium | 716 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 488 | 125 |
| Lisinopril | Lisinopril | 451 | 126 |
| Alprazolam | Alprazolam | 444 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 432 | 123 |
| Gabapentin | Gabapentin | 392 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 373 | 115 |
| Famotidine | Famotidine | 366 | 117 |
| Trazodone Hcl | Trazodone Hcl | 304 | 75 |
| Metformin Hcl | Metformin Hcl | 288 | 78 |
| Omeprazole | Omeprazole | 269 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 69 |
| Furosemide | Furosemide | 238 | 85 |
| Zolpidem Tartrate | Zolpidem Tartrate | 236 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 104 |
| Simvastatin | Simvastatin | 232 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 227 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 65 |
| Montelukast Sodium | Montelukast Sodium | 200 | 56 |
| Ozempic | Semaglutide | 187 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 173 | 44 |
| Azithromycin | Azithromycin | 167 | 122 |
| Sertraline Hcl | Sertraline Hcl | 166 | 44 |
| Tramadol Hcl | Tramadol Hcl | 165 | 29 |
| Eliquis | Apixaban | 164 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 43 |
| Potassium Chloride | Potassium Chloride | 160 | 61 |
| Lorazepam | Lorazepam | 159 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 63 |
| Carvedilol | Carvedilol | 153 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 124 | 36 |
| Allopurinol | Allopurinol | 123 | 36 |
| Bupropion Xl | Bupropion Hcl | 115 | 43 |
| Donepezil Hcl | Donepezil Hcl | 113 | 34 |
| Clonazepam | Clonazepam | 110 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 29 |
| Meloxicam | Meloxicam | 92 | 32 |
| Pregabalin | Pregabalin | 89 | 14 |
| Spironolactone | Spironolactone | 87 | 24 |
| Metformin Hcl Er | Metformin Hcl | 83 | 30 |
| Ondansetron Odt | Ondansetron | 77 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 21 |
| Memantine Hcl | Memantine Hcl | 76 | 20 |
| Synthroid | Levothyroxine Sodium | 76 | 20 |
| Ezetimibe | Ezetimibe | 75 | 20 |
| Glipizide | Glipizide | 75 | 21 |
| Prednisone | Prednisone | 75 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Glimepiride | Glimepiride | 71 | 21 |
| Atenolol | Atenolol | 65 | 17 |
| Baclofen | Baclofen | 65 | 41 |
| Buspirone Hcl | Buspirone Hcl | 65 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 49 |
| Alendronate Sodium | Alendronate Sodium | 62 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 61 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Valacyclovir | Valacyclovir Hcl | 60 | 22 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 18 |
| Fenofibrate | Fenofibrate | 54 | 15 |
| Cephalexin | Cephalexin | 53 | 43 |
| Diazepam | Diazepam | 53 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 53 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 12 |
| Xarelto | Rivaroxaban | 50 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 35 |
| Telmisartan | Telmisartan | 45 | 12 |
| Colchicine | Colchicine | 44 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 14 |
| Warfarin Sodium | Warfarin Sodium | 41 | 11 |
| Topiramate | Topiramate | 40 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 29 |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Estradiol | Estradiol | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 13 |
| Valsartan | Valsartan | 37 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 13 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 28 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 29 |
| Nitroglycerin | Nitroglycerin | 30 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 20 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Clotrimazole | Clotrimazole | 27 | 21 |
| Ramipril | Ramipril | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Indapamide | Indapamide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Benzonatate | Benzonatate | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,647.71 · 81 records | Lilly USA, LLC | AIRSUPRA, Auvelity, CONTRAVE, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, JARDIANCE, JASCAYD, KISUNLA, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, ONPATTRO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, Symbravo, TRELEGY ELLIPTA, UBRELVY, UNITHROID, VERQUVO, VYNDAMAX, VYNDAQEL, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error